钾离子竞争性酸阻滞剂在酸相关疾病中的应用  

Application of potassium competitive acid blockers in acidrelated diseases

作　　者：牛春燕 罗晓春 Chun-Yan Niu;Xiao-Chun Luo(Department of Gastroenterology,Nanjing Lishui People’s Hospital(Zhongda Hospital Lishui Branch,Southeast University),Nanjing 211200,Jiangsu Province,China;Endoscopy Center,Xiang’an Hospital,Xiamen University,Xiamen 361101,Fujian Province,China)

机构地区：[1]南京市溧水区人民医院(东南大学附属中大医院溧水分院)消化内科,江苏省南京市211200 [2]厦门大学附属翔安医院内镜中心,福建省厦门市361101

出　　处：《世界华人消化杂志》2021年第8期383-388,共6页World Chinese Journal of Digestology

摘　　要：酸相关疾病是一类消化系统中的常见慢性疾病.质子泵抑制剂现已成为治疗酸相关疾病的一线用药,然而临床应用中逐渐显现出一些局限性,如半衰期短、起效较慢、抑酸不充分、药理作用受CYP2C19基因多态性影响、夜间酸突破等,导致分酸相关疾病患者的症状不能获得充分缓解,以及难治、复发、直接的健康相关生活质量下降和经济负担增大.钾离子竞争性酸阻滞剂是一种新型抗分泌药,能够克服传统质子泵抑制剂的多种局限性,在临床应用中显示出更好的抑酸效应和安全性,可能成为解决酸相关疾病治疗中未满足的医疗需求的新策略,但也需要继续观察潜在的不良反应.本文综述了酸相关疾病治疗中面临的挑战,以及钾离子竞争性酸阻滞剂在酸相关疾病预防和治疗中的优势和前景.Acid-related diseases(ARDs)are common chronic diseases of the digestive system.Proton pump inhibitors(PPIs)have become the first-line drugs for the treatment of acid-related diseases.However,PPIs display some limitations in clinical application,such as short half-life,slow action,insufficient acid inhibition,pharmacological effects affected by CYP2C19 gene polymorphism,and nocturnal acid breakthrough,which lead to insufficient symptom remission of ARDs,as well as refractoriness,relapse,and even direct decline in health-related quality of life and increased economic burden.Potassium competitive acid blockers(P-CABs)are a class of novel anti-secretory drugs,which can overcome the limitations of traditional PPIs and show satisfactory acid inhibition effect and safety in clinical application.They may become a new strategy to solve the unsatisfied medical needs in the treatment of ARDs,but their potential adverse reactions remain to be monitored.In this article,we review the challenges in the treatment of acid-related diseases,and the advantages and prospects of P-CABs in the prevention and treatment of ARDs.

关 键 词：酸相关疾病 质子泵抑制剂 新型抗分泌药物 钾离子竞争性酸阻滞剂 

分 类 号：R573[医药卫生—消化系统]